These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38480884)

  • 41. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
    Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.
    Wagner AH; Devarakonda S; Skidmore ZL; Krysiak K; Ramu A; Trani L; Kunisaki J; Masood A; Waqar SN; Spies NC; Morgensztern D; Waligorski J; Ponce J; Fulton RS; Maggi LB; Weber JD; Watson MA; O'Conor CJ; Ritter JH; Olsen RR; Cheng H; Mukhopadhyay A; Can I; Cessna MH; Oliver TG; Mardis ER; Wilson RK; Griffith M; Griffith OL; Govindan R
    Nat Commun; 2018 Sep; 9(1):3787. PubMed ID: 30224629
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distinct mutational backgrounds and clonal architectures implicated prognostic discrepancies in small-cell carcinomas of the esophagus and lung.
    Song Z; Liu Y; Cheng G; Chang L; Yu Z; Chen M; Chen G
    Cell Death Dis; 2021 May; 12(5):472. PubMed ID: 33980813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical correlation of extensive-stage small-cell lung cancer genomics.
    Dowlati A; Lipka MB; McColl K; Dabir S; Behtaj M; Kresak A; Miron A; Yang M; Sharma N; Fu P; Wildey G
    Ann Oncol; 2016 Apr; 27(4):642-7. PubMed ID: 26802149
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies.
    Wang H; Wu S; Li Z; Zhang C; Shang X; Zhao C; Li Z; Lin J; Guo J; Wang Z
    Cancer Sci; 2023 Feb; 114(2):665-679. PubMed ID: 36178064
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
    Jin Y; Bao H; Le X; Fan X; Tang M; Shi X; Zhao J; Yan J; Xu Y; Quek K; Elamin YY; Zhang J; Futreal PA; Wistuba II; Heymach JV; Lou G; Shao L; He Q; Lin C; Wu X; Shao YW; Wang X; He J; Chen Y; Stebbing J; Chen M; Zhang J; Yu X
    Oncogene; 2020 Feb; 39(9):1846-1859. PubMed ID: 31754213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
    Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
    J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genomic features of Chinese small cell lung cancer.
    Liu J; Zhao Z; Wei S; Li B; Zhao Z
    BMC Med Genomics; 2022 May; 15(1):117. PubMed ID: 35596192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
    Melchardt T; Magnes T; Hufnagl C; Thorner AR; Ducar M; Neureiter D; Tränkenschuh W; Klieser E; Gaggl A; Rösch S; Rasp G; Hartmann TN; Pleyer L; Rinnerthaler G; Weiss L; Greil R; Egle A
    Eur J Cancer; 2018 Apr; 93():69-78. PubMed ID: 29477794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer.
    Giaccone G; He Y
    Semin Cancer Biol; 2023 Sep; 94():1-10. PubMed ID: 37244438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
    Tian Y; Zhai X; Han A; Zhu H; Yu J
    J Hematol Oncol; 2019 Jun; 12(1):67. PubMed ID: 31253167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
    Liu Y; Li Y; Liu S; Adeegbe DO; Christensen CL; Quinn MM; Dries R; Han S; Buczkowski K; Wang X; Chen T; Gao P; Zhang H; Li F; Hammerman PS; Bradner JE; Quayle SN; Wong KK
    Cancer Res; 2018 Jul; 78(13):3709-3717. PubMed ID: 29760044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.
    Gu W; Zhuang W; Zhuang M; He M; Li Z
    Diagn Pathol; 2023 Nov; 18(1):119. PubMed ID: 37924135
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy era in the treatment of small cell lung cancer.
    Araz M; Karakurt Eryilmaz M
    Med Oncol; 2021 Jun; 38(7):86. PubMed ID: 34156575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Whole exome analysis reveals the genomic profiling related to chemo-resistance in Chinese population with limited-disease small cell lung cancer.
    Yu J; Zhao S; Su Z; Song C; Wu L; Wang J; Bi N; Wang L
    Cancer Med; 2023 Jan; 12(2):1035-1050. PubMed ID: 35735600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
    Peifer M; Fernández-Cuesta L; Sos ML; George J; Seidel D; Kasper LH; Plenker D; Leenders F; Sun R; Zander T; Menon R; Koker M; Dahmen I; Müller C; Di Cerbo V; Schildhaus HU; Altmüller J; Baessmann I; Becker C; de Wilde B; Vandesompele J; Böhm D; Ansén S; Gabler F; Wilkening I; Heynck S; Heuckmann JM; Lu X; Carter SL; Cibulskis K; Banerji S; Getz G; Park KS; Rauh D; Grütter C; Fischer M; Pasqualucci L; Wright G; Wainer Z; Russell P; Petersen I; Chen Y; Stoelben E; Ludwig C; Schnabel P; Hoffmann H; Muley T; Brockmann M; Engel-Riedel W; Muscarella LA; Fazio VM; Groen H; Timens W; Sietsma H; Thunnissen E; Smit E; Heideman DA; Snijders PJ; Cappuzzo F; Ligorio C; Damiani S; Field J; Solberg S; Brustugun OT; Lund-Iversen M; Sänger J; Clement JH; Soltermann A; Moch H; Weder W; Solomon B; Soria JC; Validire P; Besse B; Brambilla E; Brambilla C; Lantuejoul S; Lorimier P; Schneider PM; Hallek M; Pao W; Meyerson M; Sage J; Shendure J; Schneider R; Büttner R; Wolf J; Nürnberg P; Perner S; Heukamp LC; Brindle PK; Haas S; Thomas RK
    Nat Genet; 2012 Oct; 44(10):1104-10. PubMed ID: 22941188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.